Captrust Financial Advisors Trims Stock Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

Captrust Financial Advisors lowered its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 14.2% in the first quarter, according to its most recent 13F filing with the SEC. The fund owned 69,348 shares of the medical research company’s stock after selling 11,450 shares during the period. Captrust Financial Advisors’ holdings in Thermo Fisher Scientific were worth $40,306,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently modified their holdings of the business. Northwest Financial Advisors purchased a new stake in Thermo Fisher Scientific during the 4th quarter worth approximately $29,000. True Wealth Design LLC increased its stake in Thermo Fisher Scientific by 1,275.0% during the 4th quarter. True Wealth Design LLC now owns 55 shares of the medical research company’s stock worth $29,000 after buying an additional 51 shares in the last quarter. LifeSteps Financial Inc. purchased a new stake in Thermo Fisher Scientific during the 1st quarter worth approximately $31,000. Headlands Technologies LLC purchased a new stake in Thermo Fisher Scientific during the 1st quarter worth approximately $32,000. Finally, Pineridge Advisors LLC purchased a new stake in Thermo Fisher Scientific during the 4th quarter worth approximately $39,000. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Insider Transactions at Thermo Fisher Scientific

In other news, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction dated Monday, June 3rd. The shares were sold at an average price of $567.28, for a total transaction of $5,672,800.00. Following the completion of the sale, the chief executive officer now owns 123,816 shares in the company, valued at $70,238,340.48. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In related news, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction dated Monday, June 3rd. The shares were sold at an average price of $567.28, for a total value of $5,672,800.00. Following the completion of the sale, the chief executive officer now owns 123,816 shares in the company, valued at $70,238,340.48. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, EVP Gianluca Pettiti sold 300 shares of the firm’s stock in a transaction dated Friday, July 26th. The shares were sold at an average price of $600.85, for a total transaction of $180,255.00. Following the completion of the sale, the executive vice president now owns 17,887 shares of the company’s stock, valued at approximately $10,747,403.95. The disclosure for this sale can be found here. Over the last quarter, insiders sold 16,784 shares of company stock worth $9,801,825. Company insiders own 0.34% of the company’s stock.

Thermo Fisher Scientific Stock Up 0.3 %

NYSE:TMO traded up $1.90 during trading hours on Tuesday, hitting $606.02. The company’s stock had a trading volume of 525,295 shares, compared to its average volume of 1,557,777. The company has a current ratio of 1.72, a quick ratio of 1.37 and a debt-to-equity ratio of 0.64. Thermo Fisher Scientific Inc. has a 52-week low of $415.60 and a 52-week high of $614.79. The stock has a market capitalization of $231.33 billion, a P/E ratio of 39.13, a price-to-earnings-growth ratio of 2.83 and a beta of 0.77. The stock has a fifty day moving average of $563.21 and a 200-day moving average of $566.38.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings data on Wednesday, July 24th. The medical research company reported $5.37 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.13 by $0.24. Thermo Fisher Scientific had a net margin of 14.69% and a return on equity of 18.22%. The company had revenue of $10.54 billion during the quarter, compared to the consensus estimate of $10.50 billion. During the same quarter in the prior year, the firm posted $5.15 earnings per share. Thermo Fisher Scientific’s revenue for the quarter was down 1.4% on a year-over-year basis. On average, equities analysts forecast that Thermo Fisher Scientific Inc. will post 21.69 earnings per share for the current year.

Thermo Fisher Scientific Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, October 15th. Stockholders of record on Friday, September 13th will be paid a dividend of $0.39 per share. The ex-dividend date of this dividend is Friday, September 13th. This represents a $1.56 annualized dividend and a dividend yield of 0.26%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 10.01%.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on TMO shares. Stifel Nicolaus boosted their target price on Thermo Fisher Scientific from $600.00 to $615.00 and gave the stock a “buy” rating in a report on Thursday, July 25th. HSBC boosted their target price on Thermo Fisher Scientific from $660.00 to $670.00 and gave the stock a “buy” rating in a report on Tuesday, April 30th. Raymond James boosted their target price on Thermo Fisher Scientific from $650.00 to $660.00 and gave the stock an “outperform” rating in a report on Thursday, July 25th. Barclays decreased their price objective on Thermo Fisher Scientific from $615.00 to $600.00 and set an “equal weight” rating on the stock in a report on Friday, June 28th. Finally, Royal Bank of Canada upped their price objective on Thermo Fisher Scientific from $660.00 to $664.00 and gave the company an “outperform” rating in a report on Thursday, July 25th. Five analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $618.94.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.